{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    10,
    19,
    20,
    22
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_2",
        "affectedSection": "Section 1.3 - Benefit-Risk Assessment",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added benefit-risk assessment specifically for Sweden."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_2",
        "affectedSection": "Global/Administrative",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated EudraCT number to 2018-004279-11."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_1",
        "affectedSection": "Schedule of Activities",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Expanded age range for Cohort 1 and added clinical assessment flexibility."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_1",
        "affectedSection": "Section 3 - Study Design",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Increased sample size and added European investigator sites."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_2",
        "reasonText": "Required for Sweden by the Swedish Medical Products Agency (MPA)",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_1",
        "reasonText": "Improve clarity and correct typographic errors",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_1",
        "reasonText": "Incorporation of revisions requested by country health authorities and IRBs/ECs",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_2",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "Benefit-risk assessment (country specific-amendment, required for Sweden)",
        "summary": "Added benefit-risk assessment for Swedish MPA compliance."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_1",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.1",
        "beforeText": "Cohort 1 age range (original)",
        "afterText": "Cohort 1 age range to include subjects 65 years of age and older",
        "summary": "Expanded Cohort 1 to include subjects 65+."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_1",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "7.2",
        "beforeText": "Temperature ranges with gaps and Fahrenheit units",
        "afterText": "Removed Fahrenheit and adjusted temperature ranges to close gaps",
        "summary": "Standardized temperature reporting and removed gaps in data ranges."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_1",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "8",
        "afterText": "Instruction for the investigator to contact the sponsor or designee for SAEs occurring within 30 days after vaccination",
        "summary": "Added specific reporting instructions for SAEs."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_1",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "9.1.2",
        "afterText": "Immunogenicity bridging analysis will be performed between each of Cohort 2 and Cohort 3 and the subset of subjects 60 through 64 years of age in Cohort 1",
        "summary": "Clarified the specific age subset for immunogenicity bridging."
      },
      {
        "id": "change_6",
        "amendmentId": "amend_1",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1",
        "beforeText": "Standard clinical assessment",
        "afterText": "Physical examination based on medical history",
        "summary": "Revised scope of clinical assessment to allow for history-based exams."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 3,
      "changeCount": 6
    }
  }
}